Roche confirmed plans to expand its partnership with Nvidia to build a large AI 'factory' aimed at accelerating drug discovery and diagnostic development, following a broader pharma push to secure top‑tier compute. The deal mirrors recent investments by other drugmakers and comes after Eli Lilly unveiled an Nvidia‑backed supercomputer. Roche said the collaboration will combine its biological datasets with Nvidia’s AI stack to scale model development, simulation, and analysis across preclinical and translational pipelines. Industry sources indicated infrastructure will support both internal R&D and partnerships with external developers. Executives framed the investment as a means to shorten cycles from target discovery to clinical candidate selection, but the move also raises questions about data governance, model validation, and regulatory engagement as AI increasingly informs decision‑making in regulated development programs.